Stocks
Intelligent OutlookREGN-
Intelligent Outlook
REGN-
Prev Close-
50D MA-
200D MA-
52W High-
Live Price
REGN 24H Rolling
0.000.00%0.00
Rolling: Last 24h | 5m
REGN
Asset Information
Company Profile
Company:REGN
Sector:Biotechnology
Industry:Biotechnology
Country:US
Employees:15,207
IPO Date:1991-04-02
Website:www.regeneron.com/
Technicals & Growth
Market Cap:$66.53B
Shares O/S:103,282,318
52W High:$844.51
52W Low:$476.49
50D MA:$584.15
200D MA:$595.74
Financial Ratios
P/E Ratio:15.43
EPS:$41.75
Profit Margin:31.41%
ROE (TTM):14.41%
ROA (TTM):11.11%
Div. Per Share:$2.64
REGN
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Loading chart library...
Financial Data (Macrotrends)
Historical Data
Loading...